Diamyd Net Income From Continuing Ops from 2010 to 2026
| DMN Stock | EUR 1.50 0.01 0.67% |
Net Loss | First Reported 2019-05-31 | Previous Quarter -43.9 M | Current Value -48.8 M | Quarterly Volatility 32.3 M |
Check Diamyd Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Diamyd Medical's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 2.2 M or Interest Expense of 0.0, as well as many indicators such as . Diamyd financial statements analysis is a perfect complement when working with Diamyd Medical Valuation or Volatility modules.
Diamyd | Net Income From Continuing Ops |
The Net Income From Continuing Ops trend for Diamyd Medical AB offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Diamyd Medical is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Diamyd Medical's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Diamyd Medical AB over the last few years. It is Diamyd Medical's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Diamyd Medical's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Diamyd Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (62,799,214) | |
| Coefficient Of Variation | (103.21) | |
| Mean Deviation | 54,397,688 | |
| Median | (32,008,000) | |
| Standard Deviation | 64,816,433 | |
| Sample Variance | 4201.2T | |
| Range | 229.8M | |
| R-Value | (0.67) | |
| Mean Square Error | 2476.8T | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | (8,584,553) | |
| Total Sum of Squares | 67218.7T |
Diamyd Net Income From Continuing Ops History
About Diamyd Medical Financial Statements
Diamyd Medical stakeholders use historical fundamental indicators, such as Diamyd Medical's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Diamyd Medical investors may analyze each financial statement separately, they are all interrelated. For example, changes in Diamyd Medical's assets and liabilities are reflected in the revenues and expenses on Diamyd Medical's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Diamyd Medical AB. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -152.8 M | -145.2 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Diamyd Stock
Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.